Authors: Lopes RD, Furtado RH, Bronhara B, Damiani LP, Barbosa LM. DOI:https://doi.org/10.1016/S0140-6736(21)01203-4 Abstract Background COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population. Methods [...]

Authors: Giannis D, allen SL, Tsang J, Flint S, Pinhasov T, Williams S PMID: 33824972 PMCID: PMC8032474 DOI: 10.1182/blood.2020010529 Abstract Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether the risk extends postdischarge has been controversial. Our prospective registry [...]

Authors: Chen CX, Wang JJ, Li H, Yuan LT, Gale RP PMID: 33990684 PMCID: PMC8119232 DOI: 10.1038/s41375-021-01266-6 Abstract We analyzed reports on safety and efficacy of JAK-inhibitors in patients with coronavirus infectious disease-2019 (COVID-19) published between January 1st and March 6th 2021 using the Newcastle-Ottawa and Jadad scales for quality assessment. We used disease severity [...]

Authors: Zhang J, Rao X, Li Y, Zhu Y, Liu G, Guo G et al. PMID: 34106642 PMCID: PMC8133047 DOI: 10.1097/MD.0000000000025876 Abstract Background: Patients infected with a virus usually lack vitamin C. High-dose vitamin C has an antiviral effect, and has been used by several researchers to treat COVID-19 by intravenous infusion, achieving good results. [...]

Authors: Jeronimo CM, Farias ME, Almeida FF, Sampaio VS, Alexandre MA, Melo GC PMID: 32785710 PMCID: PMC7454320 DOI: 10.1093/cid/ciaa1177 Abstract Background: Steroid use for coronavirus disease 2019 (COVID-19) is based on the possible role of these drugs in mitigating the inflammatory response, mainly in the lungs, triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [...]

Authors: Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Tunez I doi: https://doi.org/10.1101/2021.04.27.21255937 Abstract Background COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. Methods We present a retrospective survival study [...]

Authors: Chamie-Quintero JJ, Hibberd JA, Scheim DE doi: https://doi.org/10.5061/dryad.dv41ns1xr Abstract Objective. We aimed to identify mortality trends associated with COVID-19 deaths in Peru during April through November 2020, when mass treatments with ivermectin (IVM), a drug of Nobel Prize-honored distinction, were autonomously deployed at different times and to different extents in [...]

Authors: Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Wagshul F et al. PMID: 34375047 PMCID: PMC8088823 DOI: 10.1097/MJT.0000000000001377 Abstract Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed [...]

Authors: Lavinio A, Ercole A, Battaglini D, Magnoni S, Badenes R, Thomas W et al. PMID: 33888132 PMCID: PMC8061459 DOI: 10.1186/s13054-021-03543-3 Abstract Introduction: Critical illness from SARS-CoV-2 infection (COVID-19) is associated with a high burden of pulmonary embolism (PE) and thromboembolic events despite standard thromboprophylaxis. Available guidance is discordant, ranging from standard care to the [...]

Authors: Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV doi: https://doi.org/10.3389/fphar.2021.652688 Abstract Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, [...]